<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899377</url>
  </required_header>
  <id_info>
    <org_study_id>203818</org_study_id>
    <nct_id>NCT02899377</nct_id>
  </id_info>
  <brief_title>A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts</brief_title>
  <official_title>A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot imaging study to determine whether molecular imaging with 18^F
      fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT),
      11^C-Methionine (MET) PET/CT, and salivary gland magnetic resonance imaging (MRI) with
      Dotarem (gadoterate meglumine) have the potential to characterize and quantify disease
      manifestations in primary Sjögren's syndrome (pSS) subjects. This will be achieved by
      assessing the associations and consistency between the imaging techniques studied, clinical
      assessments (salivary and tear flow and clinical scores), laboratory biomarkers, and
      histological findings on minor salivary gland biopsy.

      In this study, healthy volunteers will be enrolled in Group A and pSS subjects in Group B.
      The subjects will be required to undergo screening and baseline assessments including
      unstimulated and stimulated salivary flow and Schirmer's test; an imaging visit (Visit 1); a
      sample collection visit (Visit 2) for repeat of selected baseline assessments and a minor
      salivary gland biopsy for pSS subjects only; and a follow-up visit. The total duration of
      participation in the study will be up to 11 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2016</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized Uptake Value (SUV) for 18F-FDG for pSS Participants in Selected Body Areas</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, pancreas, lumbar vertebra, salivary gland, spleen, and thyroid. Safety Population included all participants who underwent any procedure on or after Visit 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which is left and right region combined value has been reported for the regions of interest. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue to Reference (TR) Ratio for 18F- FDG for pSS Participants</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for the following selected body areas: aorta, liver, lumbar vertebra, muscle, pancreas, salivary gland, spleen, and thyroid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TR Ratio of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Inflammatory Volume for 18F- FDG for pSS Participants at Selected Body Areas</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUV for 11C- MET in Selected Body Areas</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 11C-MET</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TR Ratio for 11C- MET</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TR Ratio for 11C- MET of Salivary Glands, Lachrymal Gland, Parotid Gland, and Submandibular Gland</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Inflammatory Volume 11C- MET at Selected Body Areas</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-parametric MRI Derived Parameter: Apparent Diffusion Coefficient (ADC)</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Quantitative parameters like ADC assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and interquartile range (IQR) values for ADC was used for analysis. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-parametric MRI Derived Parameter: Pure Diffusion Coefficient (D)</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Quantitative parameters like pure D assessed the use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values for pure D was used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-parametric MRI Derived Parameter: Microvascular Volume Fraction</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Quantitative parameters like Microvascular Volume Fraction assessed use of multi-parametric MRI in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported. The IVIM (intra-voxel incoherent motion) model estimates two separate pools of diffusion (for a microvascular component and a tissue component). Pool one describes fraction (f) of the signal. Pool two describes fraction (1-f) of the signal. Microvascular Volume Fraction (f) is the ratio of the signal contribution of the microvascular pool (pool one) over the entire signal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-parametric MRI Derived Parameter: Exchange Rate (KTrans)</measure>
    <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
    <description>Quantitative parameters like KTrans assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net Irreversible Influx Rate Constant (Ki) From 11C-MET PET/CT</measure>
    <time_frame>0.1, 0.4, 0.6, 0.9, 1.1, 1.4, 1.6, 1.9, 2.5, 3.5, 4.5, 6.0, 8, 10, 12, 14, 17.5, 22.5, 27.5, 32.5 and 37.5 minutes post-injection</time_frame>
    <description>Blood samples were collected at indicated time points for radio-pharmacokinetic analysis of Ki. Pharmacokinetic (PK) Population included those participants in the 'Safety' population for whom a radio-pharmacokinetic sample was obtained and analyzed. Data for lower value of region (low), higher value of region (high) and right-left combined values (aggregated) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Static and Dynamic Imaging Metrics in 11C-MET</measure>
    <time_frame>0.1, 0.4, 0.6, 0.9, 1.1, 1.4, 1.6, 1.9, 2.5, 3.5, 4.5, 6.0, 8, 10, 12, 14, 17.5, 22.5, 27.5, 32.5 and 37.5 minutes post-injection</time_frame>
    <description>Blood samples were collected at indicated time points for analysis. Pearson's correlation is presented along with 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Group A: Health subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: pSS subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18F-FDG PET/CT Imaging</intervention_name>
    <description>pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG</description>
    <arm_group_label>Group B: pSS subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>11C-MET PET/CT Imaging</intervention_name>
    <description>Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.
Other Name:11C-MET</description>
    <arm_group_label>Group A: Health subjects</arm_group_label>
    <arm_group_label>Group B: pSS subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Imaging with intravenous contrast with gadoterate meglumine</intervention_name>
    <description>Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.</description>
    <arm_group_label>Group A: Health subjects</arm_group_label>
    <arm_group_label>Group B: pSS subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minor Salivary gland (labial) biopsy</intervention_name>
    <description>A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.</description>
    <arm_group_label>Group B: pSS subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GROUP A: Healthy Volunteers Subjects for both PET/CT and MRI: Aged &gt;=40 years
             inclusive at the time of signing the informed consent.

        Subjects for MRI, without PET/CT: Aged &gt;=30 years inclusive at the time of signing the
        informed consent Healthy as defined by the investigator, or medically qualified designee,
        based on a medical evaluation including medical history, physical examination, and
        laboratory tests.

          -  Group B: Primary Sjögren's Syndrome Patients Age &gt;=30 years, at the time of signing
             the informed consent. Diagnosis of pSS according to the American-European Consensus
             Group criteria Baseline unstimulated salivary flow &gt;0.0 mL/min or evidence of
             glandular reserve function (stimulated baseline salivary flow &gt;0.05 mL/min).

        Systemically active disease, ESSDAI &gt;=5 points

          -  All Subjects Body weight &gt;=50 kilogram (kg) and body mass index within the range 18.5
             to 35 kg/m^2 (inclusive)

        Male or Female, where one of the following conditions apply:

        A female subject is eligible to participate if she is not pregnant (as confirmed by a
        negative serum human chorionic gonadotrophin test) at screening, and a negative urine
        pregnancy test 4-7 days prior to Visit 1, on the day of Visit 1 (on each day of scanning),
        on Visit 2, is not lactating, and at least one of the following conditions applies:
        non-reproductive potential or reproductive potential and agrees to use contraceptive
        methods listed in the protocol from 28 days prior to Visit 1 until follow up.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the informed consent form.

        Exclusion Criteria:

          -  Diagnosis of secondary Sjögren's Syndrome.

          -  Diagnosis of another systemic autoimmune disease, apart from pSS, including but not
             limited to, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis or
             systemic vasculitis. For Group B subjects, autoimmune conditions associated with pSS
             (for example autoimmune thyroiditis, primary biliary cirrhosis or coeliac disease),
             are not included in this exclusion, but should be described in the medical history
             taken baseline. If in doubt please consult the medical monitor.

          -  Subjects with active life-threatening or organ-threatening effects of pSS meaning that
             they may not be able to complete the study visits according to the protocol (as
             determine by the investigator) (Group B).

          -  History of coagulation or bleeding disorders which would increase the risk of minor
             salivary gland biopsy (for example, but not limited to, Hemophilia A or B, Von
             Willibrand's disease, platelet function disorders; Group B).

          -  History of malignancy within 5 years of screening that, in the view of the
             investigator, in consultation with the medical monitor if required, could confound the
             results of the 18F-FDG PET/CT scan (including lymphoma associated with pSS). This does
             not include cervical carcinoma in situ or non-melanoma skin malignancy that has been
             treated with curative surgical treatment.

          -  History of unresolved acute or chronic infection that, in the view of the investigator
             in consultation with the medial monitor, if required, could confound the results of
             the 18F-FDG PET/CT.

          -  Subject with diabetes mellitus requiring insulin therapy

          -  Contraindications to MRI scanning (as assessed by MRI safety questionnaire).

          -  History of, or suffers from, claustrophobia or feel that they will be unable to lie
             still in the PET or MRI scanner for a period of up to 1 to 2 hours.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500mL within a 56 day period.

          -  Previous inclusion in a research protocol involving nuclear medicine, PET or
             radiological investigations, or as a result of occupational exposure with a
             significant radiation burden (a significant radiation burden being defined as 10mSv in
             addition to natural background radiation, in the previous 3 years including the dose
             from this study). A clinical procedure where the subject received a direct benefit (eg
             diagnostic test) will not be included in the calculation of exposure.

          -  Lack of adequate peripheral venous access for cannulation.

          -  Current participation in a study with an investigational product, or recent
             participation within 5 half lives of discontinuation the drug, or within twice the
             duration of the biological effect of the drug, whichever is longer

          -  Group A: Healthy volunteers Subject is unable to refrain from taking prescription or
             non-prescription drugs (including vitamins and dietary or herbal supplements), within
             7 days prior to Visit 1 until completion of Visit 2, unless in the opinion of the
             investigator and Sponsor the medication will not interfere with the study.

          -  Group B: pSS subjects taking immunomodulatory treatment at screening are excluded
             unless they have been on stable doses of these medicines for 6 weeks prior to
             Screening/Baseline and are expected to remain on stable doses of these medications
             until the Follow up visit. This would include drugs such as glucocorticoids,
             immunosuppressive agents (for example, hydroxychloroquine, azathioprine, methotrexate,
             mycophenolate mofetil, and biologic therapies). If in doubt, to be discussed with the
             Medical Monitor.

          -  Group B: pSS subjects receiving treatment with anti-coagulant medications, including
             but not limited to warfarin, heparin, thrombin inhibitors, and Factor Xa inhibitors,
             and aspirin, unless the subjects is able to discontinue these medications one week
             prior to minor salivary gland biopsy, or according to local guidelines. The treatment
             may be restarted 3 days after the biopsy, or according to local guidelines.

          -  History of alcohol, prescription or non-prescription drug abuse which could interfere
             with participation in the trial according to the protocol, or in the opinion of the
             investigator impacts on the physical or mental wellbeing of the subject

          -  History of allergy/hypersensitivity to study medications including local anesthesia
             (Group B), radio-isotopes or gadolinium-containing contrast agents (all subjects).

          -  Contraindications to gadolinium-containing contrast agents in accordance with product
             labeling and local guidelines

          -  Estimated GFR (Modification of Diet in Renal Disease calculation) of less than 60
             mL/min/1.73m^2 at screening.

          -  Platelet count below the laboratory normal range at screening, or prothrombin time
             above the laboratory normal range at screening (Group B).

          -  Subject with a fasting blood sugar &gt;11.1 millimoles (mmol)/Liters (L) at screening
             (defined as fasting for a minimum of 6 hours, excluding unflavored water).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <results_first_submitted>June 27, 2019</results_first_submitted>
  <results_first_submitted_qc>October 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 23, 2019</last_update_submitted>
  <last_update_submitted_qc>October 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>Primary Sjögren's Syndrome</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>11^C-MET</keyword>
  <keyword>18^F-FDG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02899377/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02899377/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a pilot imaging study using positron emission tomography (PET)/computed tomography (CT) and multi parametric magnetic resonance imaging (MRI) to investigate the potential to characterize and quantify disease manifestation in primary Sjögren’s syndrome (pSS) participants.</recruitment_details>
      <pre_assignment_details>A total of 25 participants were enrolled in the study. The study was conducted at 3 centers in the United Kingdom.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Participants</title>
          <description>Underwent an MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 millimoles (mmol)/kilogram (kg) of gadoterate meglumine and received one-time IV bolus injection of 500 megabecquerels (MBq) of carbon11-methionine (11C -MET) followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
        </group>
        <group group_id="P2">
          <title>Participants With pSS</title>
          <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-flurodeoxyglucose (FDG) followed by a PET/CT (static head to hip scan).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Participants</title>
          <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
        </group>
        <group group_id="B2">
          <title>Participants With pSS</title>
          <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="13.87"/>
                    <measurement group_id="B2" value="49.0" spread="13.70"/>
                    <measurement group_id="B3" value="48.5" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian: Central/south Asian heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian: South East Asian heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed race White Caribbean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black British</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Standardized Uptake Value (SUV) for 18F-FDG for pSS Participants in Selected Body Areas</title>
        <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, pancreas, lumbar vertebra, salivary gland, spleen, and thyroid. Safety Population included all participants who underwent any procedure on or after Visit 1.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Uptake Value (SUV) for 18F-FDG for pSS Participants in Selected Body Areas</title>
          <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, pancreas, lumbar vertebra, salivary gland, spleen, and thyroid. Safety Population included all participants who underwent any procedure on or after Visit 1.</description>
          <population>Safety Population</population>
          <units>Grams per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aorta, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9067" spread="0.49445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0683" spread="1.13564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0225" spread="0.91105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4558" spread="0.50282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2700" spread="1.02711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1067" spread="0.83496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2333" spread="0.54135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1408" spread="0.72742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aorta, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.883" spread="0.2740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.273" spread="0.2605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.105" spread="0.4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.657" spread="0.1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.874" spread="0.2511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.751" spread="0.1889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.822" spread="0.5509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aorta, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0125" spread="0.35028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2700" spread="0.53533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8242" spread="0.58906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8833" spread="0.25378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6892" spread="0.47389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1425" spread="0.58856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3475" spread="0.30266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2458" spread="0.68193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</title>
        <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which is left and right region combined value has been reported for the regions of interest. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</title>
          <description>Semi-quantitative parameters used for the assessment of glucose uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which is left and right region combined value has been reported for the regions of interest. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
          <population>Safety Population</population>
          <units>Grams per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lachrymal gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7808" spread="0.38311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0658" spread="0.34849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0658" spread="0.34849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5767" spread="0.68672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7783" spread="0.76902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7783" spread="0.76902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5200" spread="0.82131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9250" spread="0.94362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9250" spread="0.94362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.311" spread="0.3218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.515" spread="0.2934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" spread="0.5022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.818" spread="0.5957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.709" spread="0.6786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.916" spread="0.6237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5842" spread="0.18535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7125" spread="0.24264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6492" spread="0.20505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0150" spread="0.64590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2383" spread="0.71837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1275" spread="0.67216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9275" spread="0.74620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3883" spread="0.69049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1583" spread="0.67168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tissue to Reference (TR) Ratio for 18F- FDG for pSS Participants</title>
        <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for the following selected body areas: aorta, liver, lumbar vertebra, muscle, pancreas, salivary gland, spleen, and thyroid.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue to Reference (TR) Ratio for 18F- FDG for pSS Participants</title>
          <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for the following selected body areas: aorta, liver, lumbar vertebra, muscle, pancreas, salivary gland, spleen, and thyroid.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aorta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0660" spread="0.05729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7366" spread="0.11645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5096" spread="0.28568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4669" spread="0.10222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4312" spread="0.16490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1730" spread="0.38592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2625" spread="0.17400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2193" spread="0.44934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TR Ratio of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</title>
        <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>TR Ratio of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 18F-FDG for pSS Participants</title>
          <description>Semi-quantitative parameters used for the assessment of glucose uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
          <population>Safety Population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lachrymal gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8529" spread="0.12250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9201" spread="0.13587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8864" spread="0.12560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1158" spread="0.44262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2338" spread="0.47055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1749" spread="0.45273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0472" spread="0.43105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2953" spread="0.41063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1711" spread="0.40012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Inflammatory Volume for 18F- FDG for pSS Participants at Selected Body Areas</title>
        <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Inflammatory Volume for 18F- FDG for pSS Participants at Selected Body Areas</title>
          <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV</description>
          <population>Safety Population. Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUV for 11C- MET in Selected Body Areas</title>
        <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan is reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
        </group_list>
        <measure>
          <title>SUV for 11C- MET in Selected Body Areas</title>
          <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan is reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Grams per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aorta, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2700" spread="0.72709"/>
                    <measurement group_id="O2" value="2.0275" spread="0.62609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1667" spread="3.81783"/>
                    <measurement group_id="O2" value="16.4213" spread="3.31237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1733" spread="2.85382"/>
                    <measurement group_id="O2" value="5.9100" spread="1.43376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4167" spread="0.89879"/>
                    <measurement group_id="O2" value="2.3513" spread="1.01454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4492" spread="5.17911"/>
                    <measurement group_id="O2" value="31.7388" spread="5.68871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4275" spread="1.43053"/>
                    <measurement group_id="O2" value="6.6900" spread="1.05224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5100" spread="1.35700"/>
                    <measurement group_id="O2" value="5.2750" spread="1.22413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7058" spread="0.86450"/>
                    <measurement group_id="O2" value="3.1038" spread="0.79784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aorta, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.161" spread="0.2927"/>
                    <measurement group_id="O2" value="1.029" spread="0.3334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.926" spread="2.1692"/>
                    <measurement group_id="O2" value="8.916" spread="1.4380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.485" spread="0.9351"/>
                    <measurement group_id="O2" value="2.923" spread="0.5387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" spread="0.2074"/>
                    <measurement group_id="O2" value="0.926" spread="0.2365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.413" spread="3.1008"/>
                    <measurement group_id="O2" value="16.556" spread="2.9023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.650" spread="0.3745"/>
                    <measurement group_id="O2" value="2.423" spread="0.1005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.149" spread="0.6418"/>
                    <measurement group_id="O2" value="1.646" spread="0.3138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aorta, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3250" spread="0.37590"/>
                    <measurement group_id="O2" value="1.1338" spread="0.41008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7808" spread="3.01666"/>
                    <measurement group_id="O2" value="12.3438" spread="1.76812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7317" spread="1.28105"/>
                    <measurement group_id="O2" value="3.8775" spread="0.62923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3675" spread="0.40656"/>
                    <measurement group_id="O2" value="1.3100" spread="0.29544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4683" spread="4.29608"/>
                    <measurement group_id="O2" value="26.7913" spread="6.21700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3633" spread="1.16624"/>
                    <measurement group_id="O2" value="5.0600" spread="0.83111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6975" spread="0.61556"/>
                    <measurement group_id="O2" value="3.4100" spread="0.35633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6000" spread="0.65448"/>
                    <measurement group_id="O2" value="2.0525" spread="0.29673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 11C-MET</title>
        <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
        </group_list>
        <measure>
          <title>SUV of Lachrymal Gland, Parotid Gland, and Submandibular Gland for 11C-MET</title>
          <description>Semi-quantitative parameters used for the assessment of uptake included Mean, Peak and Max SUV for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported. SUV is a mathematically derived ratio of tissue radioactivity concentration and the injected dose of radioactivity per kilogram of the participant's body weight at a given point in time.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Grams per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lachrymal gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9133" spread="1.00469"/>
                    <measurement group_id="O2" value="2.5513" spread="1.00049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1483" spread="1.02205"/>
                    <measurement group_id="O2" value="3.1250" spread="1.49196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1483" spread="1.02205"/>
                    <measurement group_id="O2" value="3.1250" spread="1.49196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3933" spread="1.31072"/>
                    <measurement group_id="O2" value="5.9038" spread="1.01547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9492" spread="1.22415"/>
                    <measurement group_id="O2" value="6.3750" spread="1.09929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9492" spread="1.22415"/>
                    <measurement group_id="O2" value="6.3750" spread="1.09929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8583" spread="1.78484"/>
                    <measurement group_id="O2" value="6.2150" spread="1.06158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4692" spread="1.77872"/>
                    <measurement group_id="O2" value="6.5488" spread="0.94266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated, Max SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4692" spread="1.77872"/>
                    <measurement group_id="O2" value="6.5488" spread="0.94266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.312" spread="0.6048"/>
                    <measurement group_id="O2" value="1.703" spread="0.5810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.462" spread="0.6490"/>
                    <measurement group_id="O2" value="2.056" spread="0.7874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.525" spread="0.8740"/>
                    <measurement group_id="O2" value="3.505" spread="0.5637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.925" spread="0.8679"/>
                    <measurement group_id="O2" value="3.648" spread="0.5709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.388" spread="1.1855"/>
                    <measurement group_id="O2" value="3.923" spread="0.4941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Mean SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.648" spread="1.2128"/>
                    <measurement group_id="O2" value="4.191" spread="0.5410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3525" spread="0.59715"/>
                    <measurement group_id="O2" value="1.7738" spread="0.66125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4958" spread="0.65626"/>
                    <measurement group_id="O2" value="2.1688" spread="0.99580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4233" spread="0.62222"/>
                    <measurement group_id="O2" value="1.9713" spread="0.81354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4367" spread="1.22748"/>
                    <measurement group_id="O2" value="4.9000" spread="0.92893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9175" spread="1.18255"/>
                    <measurement group_id="O2" value="5.1663" spread="0.85276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6767" spread="1.18792"/>
                    <measurement group_id="O2" value="5.0325" spread="0.89020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8025" spread="1.53196"/>
                    <measurement group_id="O2" value="4.8588" spread="0.86087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2992" spread="1.63167"/>
                    <measurement group_id="O2" value="5.3100" spread="0.89113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated, Peak SUV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0517" spread="1.56359"/>
                    <measurement group_id="O2" value="5.0838" spread="0.86490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TR Ratio for 11C- MET</title>
        <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
        </group_list>
        <measure>
          <title>TR Ratio for 11C- MET</title>
          <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: aorta, liver, muscle, lumbar vertebra, pancreas, salivary gland, spleen, and thyroid. Data from static scan has been reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aorta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1352" spread="0.06738"/>
                    <measurement group_id="O2" value="1.0910" spread="0.04942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1513" spread="3.13572"/>
                    <measurement group_id="O2" value="12.8649" spread="3.46136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Vertebra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1158" spread="0.85314"/>
                    <measurement group_id="O2" value="3.9731" spread="0.80867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1914" spread="0.26802"/>
                    <measurement group_id="O2" value="1.3354" spread="0.34831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5403" spread="4.62140"/>
                    <measurement group_id="O2" value="29.8331" spread="15.21426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salivary gland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0974" spread="1.30105"/>
                    <measurement group_id="O2" value="5.2805" spread="1.44642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spleen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2872" spread="0.67470"/>
                    <measurement group_id="O2" value="3.5414" spread="0.81253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3002" spread="0.63142"/>
                    <measurement group_id="O2" value="2.1213" spread="0.49670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TR Ratio for 11C- MET of Salivary Glands, Lachrymal Gland, Parotid Gland, and Submandibular Gland</title>
        <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
        </group_list>
        <measure>
          <title>TR Ratio for 11C- MET of Salivary Glands, Lachrymal Gland, Parotid Gland, and Submandibular Gland</title>
          <description>Semi-quantitative parameters used for the assessment of uptake included TR ratio for following selected body areas: lachrymal gland, parotid gland, and submandibular gland. Data from static scan for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lachrymal gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2007" spread="0.55639"/>
                    <measurement group_id="O2" value="1.8219" spread="0.62711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3178" spread="0.59115"/>
                    <measurement group_id="O2" value="2.1965" spread="0.76588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lachrymal gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2594" spread="0.57188"/>
                    <measurement group_id="O2" value="2.0094" spread="0.68084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1810" spread="1.44525"/>
                    <measurement group_id="O2" value="5.1570" spread="1.61371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6198" spread="1.41338"/>
                    <measurement group_id="O2" value="5.4621" spread="1.73285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4003" spread="1.41542"/>
                    <measurement group_id="O2" value="5.3096" spread="1.67006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5766" spread="1.61682"/>
                    <measurement group_id="O2" value="5.0230" spread="1.20994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0126" spread="1.61982"/>
                    <measurement group_id="O2" value="5.4796" spread="1.30126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7946" spread="1.60578"/>
                    <measurement group_id="O2" value="5.2513" spread="1.24653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Inflammatory Volume 11C- MET at Selected Body Areas</title>
        <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
          <group group_id="O2">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Inflammatory Volume 11C- MET at Selected Body Areas</title>
          <description>There were no anatomically relevant areas indicative of inflamed tissue and/or focal uptake within the organs that would warrant calculation of TIV.</description>
          <population>Safety Population. Data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multi-parametric MRI Derived Parameter: Apparent Diffusion Coefficient (ADC)</title>
        <description>Quantitative parameters like ADC assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and interquartile range (IQR) values for ADC was used for analysis. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Multi-parametric MRI Derived Parameter: Apparent Diffusion Coefficient (ADC)</title>
          <description>Quantitative parameters like ADC assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and interquartile range (IQR) values for ADC was used for analysis. Data for lower value of region (low), higher value of region (high), and aggregated value which includes left and right region combined value has been reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>10^-3 square millimeter per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parotid Gland, Low, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.511" spread="0.0314"/>
                    <measurement group_id="O2" value="0.516" spread="0.0356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.581" spread="0.0275"/>
                    <measurement group_id="O2" value="0.646" spread="0.0412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.544" spread="0.0264"/>
                    <measurement group_id="O2" value="0.582" spread="0.0408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.549" spread="0.0321"/>
                    <measurement group_id="O2" value="0.765" spread="0.0693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.674" spread="0.0309"/>
                    <measurement group_id="O2" value="0.928" spread="0.0714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.602" spread="0.0303"/>
                    <measurement group_id="O2" value="0.809" spread="0.0695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Low, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.091" spread="0.0476"/>
                    <measurement group_id="O2" value="1.011" spread="0.0607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.153" spread="0.0451"/>
                    <measurement group_id="O2" value="1.117" spread="0.0524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.120" spread="0.0460"/>
                    <measurement group_id="O2" value="1.069" spread="0.0539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.469" spread="0.0377"/>
                    <measurement group_id="O2" value="1.410" spread="0.0924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.540" spread="0.0461"/>
                    <measurement group_id="O2" value="1.551" spread="0.0833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.506" spread="0.0396"/>
                    <measurement group_id="O2" value="1.474" spread="0.0767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multi-parametric MRI Derived Parameter: Pure Diffusion Coefficient (D)</title>
        <description>Quantitative parameters like pure D assessed the use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values for pure D was used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Multi-parametric MRI Derived Parameter: Pure Diffusion Coefficient (D)</title>
          <description>Quantitative parameters like pure D assessed the use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values for pure D was used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>10^-3 square millimeter per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parotid Gland, Low, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.437" spread="0.0343"/>
                    <measurement group_id="O2" value="0.449" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.503" spread="0.0336"/>
                    <measurement group_id="O2" value="0.529" spread="0.0296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.468" spread="0.0344"/>
                    <measurement group_id="O2" value="0.493" spread="0.0322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.553" spread="0.0361"/>
                    <measurement group_id="O2" value="0.547" spread="0.0440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.733" spread="0.0377"/>
                    <measurement group_id="O2" value="0.681" spread="0.0641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.636" spread="0.0324"/>
                    <measurement group_id="O2" value="0.608" spread="0.0443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Low, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.771" spread="0.0269"/>
                    <measurement group_id="O2" value="0.621" spread="0.0492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.807" spread="0.0287"/>
                    <measurement group_id="O2" value="0.715" spread="0.0450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.787" spread="0.0274"/>
                    <measurement group_id="O2" value="0.676" spread="0.0457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.941" spread="0.0445"/>
                    <measurement group_id="O2" value="0.733" spread="0.0924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" spread="0.0402"/>
                    <measurement group_id="O2" value="0.814" spread="0.0887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.993" spread="0.0409"/>
                    <measurement group_id="O2" value="0.807" spread="0.0905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multi-parametric MRI Derived Parameter: Microvascular Volume Fraction</title>
        <description>Quantitative parameters like Microvascular Volume Fraction assessed use of multi-parametric MRI in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported. The IVIM (intra-voxel incoherent motion) model estimates two separate pools of diffusion (for a microvascular component and a tissue component). Pool one describes fraction (f) of the signal. Pool two describes fraction (1-f) of the signal. Microvascular Volume Fraction (f) is the ratio of the signal contribution of the microvascular pool (pool one) over the entire signal.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Multi-parametric MRI Derived Parameter: Microvascular Volume Fraction</title>
          <description>Quantitative parameters like Microvascular Volume Fraction assessed use of multi-parametric MRI in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported. The IVIM (intra-voxel incoherent motion) model estimates two separate pools of diffusion (for a microvascular component and a tissue component). Pool one describes fraction (f) of the signal. Pool two describes fraction (1-f) of the signal. Microvascular Volume Fraction (f) is the ratio of the signal contribution of the microvascular pool (pool one) over the entire signal.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parotid Gland, Low, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135" spread="0.0084"/>
                    <measurement group_id="O2" value="0.135" spread="0.0122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="0.0082"/>
                    <measurement group_id="O2" value="0.172" spread="0.0155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.149" spread="0.0090"/>
                    <measurement group_id="O2" value="0.156" spread="0.0145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.204" spread="0.0126"/>
                    <measurement group_id="O2" value="0.205" spread="0.0101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, IQR, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.233" spread="0.0143"/>
                    <measurement group_id="O2" value="0.233" spread="0.0102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, IQR, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.219" spread="0.0135"/>
                    <measurement group_id="O2" value="0.217" spread="0.0097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Low, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.131" spread="0.0068"/>
                    <measurement group_id="O2" value="0.139" spread="0.0068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.0098"/>
                    <measurement group_id="O2" value="0.164" spread="0.0127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.140" spread="0.0079"/>
                    <measurement group_id="O2" value="0.151" spread="0.0100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.198" spread="0.0164"/>
                    <measurement group_id="O2" value="0.238" spread="0.0263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, Median, n=12, 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.223" spread="0.0167"/>
                    <measurement group_id="O2" value="0.271" spread="0.0257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, Median, n=12, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.210" spread="0.0165"/>
                    <measurement group_id="O2" value="0.243" spread="0.0273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multi-parametric MRI Derived Parameter: Exchange Rate (KTrans)</title>
        <description>Quantitative parameters like KTrans assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
        <time_frame>Visit 1: Within 6 weeks after Baseline</time_frame>
        <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Multi-parametric MRI Derived Parameter: Exchange Rate (KTrans)</title>
          <description>Quantitative parameters like KTrans assessed use of multi-parametric MRI in the assessment of uptake in selected body areas like lachrymal gland, parotid gland, and submandibular gland. The median and IQR values were used for analysis. Data for lower value of region, higher value of region, and aggregated value which includes left and right region combined value has been reported.</description>
          <population>Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).</population>
          <units>Per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parotid Gland, Low, IQR, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.618" spread="3.8286"/>
                    <measurement group_id="O2" value="22.492" spread="9.8803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, IQR, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.821" spread="6.7497"/>
                    <measurement group_id="O2" value="30.199" spread="13.2411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, IQR, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.701" spread="5.5677"/>
                    <measurement group_id="O2" value="27.213" spread="12.3396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, IQR, n=9, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.548" spread="4.6510"/>
                    <measurement group_id="O2" value="0.459" spread="0.0850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, IQR, n=9, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.192" spread="9.3625"/>
                    <measurement group_id="O2" value="19.914" spread="17.5121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, IQR, n=11, 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.191" spread="6.1313"/>
                    <measurement group_id="O2" value="1.801" spread="0.8246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Low, Median, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.598" spread="2.5910"/>
                    <measurement group_id="O2" value="3.326" spread="1.3677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High, Median, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.841" spread="4.3542"/>
                    <measurement group_id="O2" value="9.323" spread="4.9569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated, Median, n=12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.061" spread="3.4227"/>
                    <measurement group_id="O2" value="7.450" spread="3.8203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low, Median, n=9, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.789" spread="11.7785"/>
                    <measurement group_id="O2" value="0.775" spread="0.2742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High, Median, n=9, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.315" spread="12.2640"/>
                    <measurement group_id="O2" value="1.606" spread="0.5826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated, Median, n=11,11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.146" spread="9.8325"/>
                    <measurement group_id="O2" value="1.421" spread="0.6603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Irreversible Influx Rate Constant (Ki) From 11C-MET PET/CT</title>
        <description>Blood samples were collected at indicated time points for radio-pharmacokinetic analysis of Ki. Pharmacokinetic (PK) Population included those participants in the 'Safety' population for whom a radio-pharmacokinetic sample was obtained and analyzed. Data for lower value of region (low), higher value of region (high) and right-left combined values (aggregated) is presented.</description>
        <time_frame>0.1, 0.4, 0.6, 0.9, 1.1, 1.4, 1.6, 1.9, 2.5, 3.5, 4.5, 6.0, 8, 10, 12, 14, 17.5, 22.5, 27.5, 32.5 and 37.5 minutes post-injection</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Net Irreversible Influx Rate Constant (Ki) From 11C-MET PET/CT</title>
          <description>Blood samples were collected at indicated time points for radio-pharmacokinetic analysis of Ki. Pharmacokinetic (PK) Population included those participants in the 'Safety' population for whom a radio-pharmacokinetic sample was obtained and analyzed. Data for lower value of region (low), higher value of region (high) and right-left combined values (aggregated) is presented.</description>
          <population>PK Population</population>
          <units>Milliliter/centimeter cube/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parotid Gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0574" spread="0.02282"/>
                    <measurement group_id="O2" value="0.0425" spread="0.02200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0608" spread="0.02411"/>
                    <measurement group_id="O2" value="0.0472" spread="0.02293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid Gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0593" spread="0.02332"/>
                    <measurement group_id="O2" value="0.0448" spread="0.02211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0598" spread="0.02051"/>
                    <measurement group_id="O2" value="0.0383" spread="0.01756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0626" spread="0.02137"/>
                    <measurement group_id="O2" value="0.0422" spread="0.01916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Submandibular Gland, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0614" spread="0.02085"/>
                    <measurement group_id="O2" value="0.0407" spread="0.01863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Static and Dynamic Imaging Metrics in 11C-MET</title>
        <description>Blood samples were collected at indicated time points for analysis. Pearson's correlation is presented along with 95% confidence interval.</description>
        <time_frame>0.1, 0.4, 0.6, 0.9, 1.1, 1.4, 1.6, 1.9, 2.5, 3.5, 4.5, 6.0, 8, 10, 12, 14, 17.5, 22.5, 27.5, 32.5 and 37.5 minutes post-injection</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Participants</title>
            <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
          </group>
          <group group_id="O2">
            <title>Participants With pSS</title>
            <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Static and Dynamic Imaging Metrics in 11C-MET</title>
          <description>Blood samples were collected at indicated time points for analysis. Pearson's correlation is presented along with 95% confidence interval.</description>
          <population>PK Population</population>
          <units>Grams per milliliter</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Max SUV, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" lower_limit="-0.736" upper_limit="0.670"/>
                    <measurement group_id="O2" value="0.915" lower_limit="0.719" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max SUV, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" lower_limit="-0.754" upper_limit="0.647"/>
                    <measurement group_id="O2" value="0.884" lower_limit="0.629" upper_limit="0.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max SUV, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.100" lower_limit="-0.752" upper_limit="0.650"/>
                    <measurement group_id="O2" value="0.891" lower_limit="0.648" upper_limit="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean SUV, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" lower_limit="-0.625" upper_limit="0.770"/>
                    <measurement group_id="O2" value="0.895" lower_limit="0.660" upper_limit="0.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean SUV, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" lower_limit="-0.633" upper_limit="0.764"/>
                    <measurement group_id="O2" value="0.786" lower_limit="0.387" upper_limit="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak SUV, Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.045" lower_limit="-0.681" upper_limit="0.727"/>
                    <measurement group_id="O2" value="0.929" lower_limit="0.761" upper_limit="0.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak SUV, High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" lower_limit="-0.677" upper_limit="0.730"/>
                    <measurement group_id="O2" value="0.866" lower_limit="0.582" upper_limit="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak SUV, Aggregated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" lower_limit="-0.685" upper_limit="0.723"/>
                    <measurement group_id="O2" value="0.906" lower_limit="0.692" upper_limit="0.974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious adverse events and serious adverse events (SAE) were collected up to 11 weeks</time_frame>
      <desc>Non-serious adverse events and SAEs were collected for Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Participants</title>
          <description>Underwent an MRI of the salivary glands with one-time IV bolus injection of 0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injection of 500 MBq of 11C-MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)</description>
        </group>
        <group group_id="E2">
          <title>Participants With pSS</title>
          <description>Underwent an MRI of the salivary glands with IV bolus injection of &lt;=0.1 mmol/kg of gadoterate meglumine and received one-time IV bolus injections: 500 MBq of 11C-MET and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Reponse Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343 ext 1</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

